Abstract 427P
Background
Several important factors affect directly or indirectly the quality of life of women with cancer in India. Several unmet needs were found to be unaddressed. This program aims to empower the patient, improve quality of life and encourage them to actively participate in the healing process. Hospitals and oncologists are challenged to develop programs that support the growing number of cancer patients. Failure to address leads to decreased compliance and outcomes.
Methods
Patients will be enrolled to participate in the introductory half a day program after obtaining informed consent and completing the pre assessment form (physical, psychological and socio-economic domains, along with demography, diagnosis and details of treatment received). Program deals with confidence building tips on grooming, Skin and hair care, management of external prosthesis and wigs, lymphedema prevention, Nutritional advice, De-stressing and relaxation techniques Functional exercises for fitness and rehabilitation through supervised fitness and restorative yoga practices. Following the introductory program women are invited to join the 5 day session. The main intervention during this period is supervised yoga, motivation and counseling, meditative practices, guided relaxation, music, dance therapy. The tools used for assessment pre and post intervention are the assessment questionnaire and Hospital Anxiety and Depression (HADS) scale. Many of the physical problems in these women led to emotional problems such as anxiety and depression hence the HADS scale was used.
Results
370 patients were enrolled in the study-86% of patients had breast cancer. Age ranged between 26-76 years. 75% of patients were below 60 years. 18% of the patients below 40 years had breast cancer. The burden of unmet needs was primarily issues related to appearance, hair loss, skin changes, body image, arm swelling, impairment of cognitive factors and emotional problems like depression, anxiety and worry. The percentage of patients with anxiety and depression pre and post interventionTable:
427P
HADS DEPRESSION SCORE | PRE-INTERVENTION | POST-INTERVENTION |
---|---|---|
BORDER LINE (8-10) | 12.50% | 0% |
ABNORMAL (11-21) | 12.50% | 0% |
HADS ANXIETY SCORE | PRE-INTERVENTION | POST-INTERVENTION |
BORDER LINE (8-10) | 18.80% | 0% |
ABNORMAL (11-21) | 37.50% | 0% |
Conclusions
This preliminary study shows that such unique, multidimensional supportive care programs have a significant impact on quality of life through treatment into survivorship phase.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
P.P. Bapsy.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience
Presenter: Yvonne Ang
Session: Poster display session
Resources:
Abstract
498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study
Presenter: Shang-gin Wu
Session: Poster display session
Resources:
Abstract
501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Presenter: Xin Gao
Session: Poster display session
Resources:
Abstract
502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
Presenter: Masaki Kanazu
Session: Poster display session
Resources:
Abstract
482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo De Marinis
Session: Poster display session
Resources:
Abstract
483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
Presenter: Rafael Rosell
Session: Poster display session
Resources:
Abstract
484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
Presenter: Maya Gottfried
Session: Poster display session
Resources:
Abstract
491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
Presenter: Chia-I Shen
Session: Poster display session
Resources:
Abstract
510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract
496P - Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs
Presenter: Taira Ninomaru
Session: Poster display session
Resources:
Abstract